Blood Sparing Strategies: Omni-stat Routinary Use in Cardiac Surgery. A Prospective Randomized Study.

Summary

The study enrolles all consecutive patients undergoing cardiac surgery at the European Hospital, Rome. The population undergoes randomization to receive usual surgical hemostasis or added topical application of Omni-stat Celox. The two populations are followed up prospectively as regarding blood loss and need for blood transfusions, as well as adverse events at 30 days after surgery.

Timeline

Start

2010-01

Primary completion

2010-08

Completion

2010-09

Outcome

Outcome not reported

Stopped: “Lack of product due to industrial changes in the manufacturing process altering the final product.”

Drugs

Indications